Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $73.2 million.

  • Zenas BioPharma's Total Non-Current Liabilities changed N/A to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year change of. This contributed to the annual value of $218000.0 for FY2024, which is 9907.29% down from last year.
  • Zenas BioPharma's Total Non-Current Liabilities amounted to $73.2 million in Q3 2025.
  • Zenas BioPharma's 5-year Total Non-Current Liabilities high stood at $73.2 million for Q3 2025, and its period low was $218000.0 during Q4 2024.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $23.5 million (2023), whereas its average is $32.3 million.
  • Within the past 5 years, the most significant YoY rise in Zenas BioPharma's Total Non-Current Liabilities was 9907.29% (2024), while the steepest drop was 9907.29% (2024).
  • Zenas BioPharma's Total Non-Current Liabilities (Quarter) stood at $23.5 million in 2023, then crashed by 99.07% to $218000.0 in 2024, then skyrocketed by 33463.76% to $73.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $73.2 million for Q3 2025, versus $218000.0 for Q4 2024 and $23.5 million for Q4 2023.